Research & Regulatory News

Amycretin's Move to Phase 3

UKPWritten and published by UK Peptides2 min readUpdated 3 cited sources

The short answer

Novo Nordisk advanced amycretin, a unimolecular GLP-1 and amylin receptor agonist, into Phase 3 development in 2026 for both subcutaneous and oral formulations. The supporting subcutaneous data was a phase 1b/2a randomised study published in the Lancet in July 2025.

Key facts

Compound
Amycretin, Novo Nordisk
Class
Unimolecular GLP-1 + amylin receptor agonist
Formulations
Subcutaneous and oral
Supporting study
Phase 1b/2a, Lancet 2025 (PMID 40550231)
Phase 3 start
2026, obesity and type 2 diabetes
Contrast
CagriSema combines two molecules

What amycretin is

One molecule engaging both the GLP-1 receptor and the amylin receptor. That distinguishes it from CagriSema, which achieves a similar combination by pairing cagrilintide with semaglutide as two separate molecules in one injection. Amycretin is the single-molecule approach to the same pharmacological pairing.

Why the single-molecule route is pursued

One pharmacokinetic profile. Two separate agents each have their own absorption, distribution and clearance, and keeping them matched is a real formulation problem. A single molecule cannot fall out of step with itself. The same argument that motivates the multi-agonist incretins.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

What the published evidence was

Dahl and colleagues reported a phase 1b/2a randomised controlled study of subcutaneous amycretin in the Lancet in July 2025. Phase 1b/2a is early: the questions are safety, tolerability, pharmacokinetics and initial signals of activity, in small numbers over short durations.

What advancing to Phase 3 does and does not indicate

It indicates a sponsor's commercial and scientific judgement that the early data justifies a very large investment. It does not indicate efficacy has been established. That is what Phase 3 exists to test. Compounds enter Phase 3 and fail there routinely, and the danuglipron programme shows that even meeting objectives does not guarantee continuation.

Why the oral formulation is the more interesting half

An orally available peptide is a much harder problem than an oral small molecule, because peptides are digested. Oral semaglutide solves it with an absorption enhancer and strict administration conditions. Whether amycretin's oral form performs adequately in Phase 3 is a more open question than the subcutaneous form's.

What this does not concern

Amycretin is investigational and holds no marketing authorisation anywhere. It is not available outside registered clinical trials, and no research material is related to it or is an alternative to it.

Frequently asked questions

How does amycretin differ from CagriSema?

Amycretin is one molecule engaging both receptors. CagriSema combines two separate molecules, cagrilintide and semaglutide, in one injection.

What evidence supported the move to Phase 3?

A phase 1b/2a randomised study of the subcutaneous form published in the Lancet in July 2025, early-stage data on safety, tolerability and initial activity.

Does entering Phase 3 mean it works?

No. Phase 3 exists to test that. Compounds enter and fail there routinely.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More Research & Regulatory News articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.